Immunome Inc’s filing revealed that its Director BIENAIME JEAN JACQUES acquired Company’s shares for reported $60684.0 on Mar 25 ’25. In the deal valued at $7.78 per share,7,800 shares were bought. As a result of this transaction, BIENAIME JEAN JACQUES now holds 31,415 shares worth roughly $0.24 million.
Then, SIEGALL CLAY B bought 137,100 shares, generating $999,459 in total proceeds. Upon buying the shares at $7.29, the President and CEO now owns 806,736 shares.
Before that, BIENAIME JEAN JACQUES bought 7,000 shares. Immunome Inc shares valued at $57,470 were divested by the Director at a price of $8.21 per share. As a result of the transaction, BIENAIME JEAN JACQUES now holds 23,615 shares, worth roughly $0.18 million.
Lake Street initiated its Immunome Inc [IMNM] rating to a Buy in a research note published on April 02, 2025; the price target was $23. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Piper Sandler began covering IMNM with “an Overweight” recommendation on May 31, 2024. JP Morgan started covering the stock on April 30, 2024. It rated IMNM as “an Overweight”.
Price Performance Review of IMNM
On Tuesday, Immunome Inc [NASDAQ:IMNM] saw its stock fall -10.29% to $7.62. Over the last five days, the stock has lost -10.71%. Immunome Inc shares have fallen nearly -28.20% since the year began. Nevertheless, the stocks have fallen -49.06% over the past one year. While a 52-week high of $16.81 was reached on 02/10/25, a 52-week low of $5.15 was recorded on 04/09/25. SMA at 50 days reached $8.02, while 200 days put it at $11.39.
Levels Of Support And Resistance For IMNM Stock
The 24-hour chart illustrates a support level at 7.28, which if violated will result in even more drops to 6.94. On the upside, there is a resistance level at 8.24. A further resistance level may holdings at 8.85. The Relative Strength Index (RSI) on the 14-day chart is 44.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.77%. Stochastics %K at 62.05% indicates the stock is a holding.
The most recent change occurred on April 15, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
